Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simcere Pharmaceutical GroupSMHGF 96 Earnings per Share (Diluted) is $0.09 as of Dec. 2025. GuruFocus rates SMHGF with a GF Score™ of 96/100 and a GF Value™ of $1.30 (Fairly Valued). Among 785 Drug Manufacturers companies, Simcere Pharmaceutical Group ranks better than 69.17% on this metric.
During the past 9 years, Simcere Pharmaceutical Group's highest 3-Year average EPS without NRI Growth Rate was 22.70% per year. The lowest was -10.90% per year. And the median was 5.75% per year.
Simcere Pharmaceutical Group (OTCPK:SMHGF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Simcere Pharmaceutical Group Earnings per Share (Diluted) Related Terms
Simcere Pharmaceutical Group Earnings per Share (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group Earnings per Share (Diluted) Chart
SMHGF vs ZTS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's PE Ratio distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's PE Ratio falls into.
Simcere Pharmaceutical Group Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Simcere Pharmaceutical Group's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.09
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.09 mean?
Simcere Pharmaceutical Group (SMHGF) has a Earnings per Share (Diluted) of $0.09 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Simcere Pharmaceutical Group and its competitors. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #242 out of 785 companies in the Drug Manufacturers industry, placing it in the top 30.8%.
Is Simcere Pharmaceutical Group's Earnings per Share (Diluted) too high?
Simcere Pharmaceutical Group's current Earnings per Share (Diluted) is $0.09. The Drug Manufacturers industry median Earnings per Share (Diluted) is 9.90. Simcere Pharmaceutical Group's value of $0.09 is 99.1% below this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #242 out of 785 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Simcere Pharmaceutical Group has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Earnings per Share (Diluted) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #242 out of 785 companies for Earnings per Share (Diluted). This puts Simcere Pharmaceutical Group in the upper half of its industry. The industry median Earnings per Share (Diluted) is 9.90. Simcere Pharmaceutical Group's value of $0.09 is 99.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.90, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current Earnings per Share (Diluted) of $0.09 is 99.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current Earnings per Share (Diluted) is $0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (SMHGF) is currently considered Fairly Valued. The stock's GF Value™ is $1.30, compared to a current price of $1.35 — trading 3.8% above its estimated fair value. The current Earnings per Share (Diluted) is $0.09 and 99.1% below the Drug Manufacturers industry median of 9.90. Simcere Pharmaceutical Group's overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Simcere Pharmaceutical Group (SMHGF), the current Earnings per Share (Diluted) is $0.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (SMHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.35 is trading 3.8% above its estimated GF Value™ of $1.30.
GuruFocus considers Simcere Pharmaceutical Group to be Fairly Valued.
Key valuation signals for SMHGF:
Earnings per Share (Diluted): $0.09
GF Value™: $1.30 vs. price of $1.35 (3.8% above fair value)
Industry Position: 99.1% below the Drug Manufacturers median (#242 of 785)
No single metric tells the full story. See the SMHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
96GF Score
Get the complete analysis for SMHGF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMHGF has been successfully added to your 
